Intended for healthcare professionals


Drug company Vifor is investigated for allegedly spreading misinformation about competitor

BMJ 2022; 377 doi: (Published 22 June 2022) Cite this as: BMJ 2022;377:o1536
  1. Elisabeth Mahase
  1. The BMJ

The European Commission has opened an antitrust investigation into whether the Swiss drug company Vifor Pharma restricted competition by illegally disparaging its closest and potentially only European competitor for intravenous iron treatment.

The commission said that it had “indications” that for many years Vifor may have been disparaging Monofer—an iron deficiency treatment manufactured by Pharmacosmos—by spreading misleading …

View Full Text

Log in

Log in through your institution


* For online subscription